Unity Biotechnology, Inc. (NASDAQ:UBX) traded at $3.53 at last check on Tuesday, Sep 15, making an upward move of 13.32% on its previous day’s price.

Looking at the stock we see that its previous close was $3.12 and the beta (5Y monthly) reads 0 with the day’s price range being $3.1600 – 3.7400. The company has a 12-month trailing PE ratio of 0. In terms of its 52-week price range, UBX has a high of $15.44 and a low of $2.72. The company’s stock has gained about -71.6% over that past 30 days.

Unity has a market cap of $188.75 Million and is expected to release its quarterly earnings report on July 31, 2020. With its Forward Dividend at 0 and a yield of 0%, the company’s investors could be worried for the UBX stock to lose ahead of the earnings release. Estimates by analysts give the company expected earnings per share (EPS) of -$0.5, with the EPS growth for the year declined at -$2.22 for 2020 and -$1.7 for next year. These figures represent 0.18% and at -0.23% growth in EPS for the two years respectively.

On the other hand, looking at the outlook for the UBX stock, short term indicators assign the stock an average of 50% Sell, while medium term indicators assign it an average of 100% Sell. Long term indicators on average place the stock in the category of 50% Sell.

Based on estimates by 6 analysts where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 5 have rated the Unity Biotechnology, Inc. (UBX) stock as a Hold, while 1 rate it as a Buy. None analysts rate it as outperform while none of them rated it as underperform, whereas none suggests the stock as a Sell. The stock has an overall rating of Hold and investors could take advantage and scoop up stock of the company.

Looking further, we note that the PEG ratio for the UBX stock currently stands at 0, and the current price level is 12.48% off its SMA20 and -48.88% from its 50-day simple moving average. The RSI (14) is pointing at 37.36 while the volatility over the past week is 9.09% and jumps to 10.53% over the past one month. The beta value is 0, while the average true range (ATR) is currently pointing at 0.72. The average price target for the stock over the next 12 months is $5.67, with the estimates having a low of $4 and a high of $12. These price ends are 13.31% and +239.94% off the current price level respectively, although investors could be excited at the prospect of a +27.48% if the UBX share price touches on the median price of $4.5.

Let’s briefly compare Unity (UBX) stock to its peers. We find that today’s price change of +13.32% and -52.62% over the past 12 months for UBX competes that of Amgen Inc (AMGN), which has seen its stock price rise 0.65% in the latest trading session and is +27.96% over the last one year. Another of its peers Bristol-Myers Squibb Company (BMY) has dropped -0.28% today, and is +20.34% up over the past year, while Gilead Sciences Inc (GILD) is also up 13.32% yet its price remains in the red at -52.62% over the same period. Amgen has a P/E ratio of 20.29 compared to Unity’s 0 and Bristol-Myers 0. In contrast to these companies, both the S&P 500 Index and the Dow Jones Industrial are today at 0.52% and 0.01%, respectively, in early deals.

Coming back to Unity Biotechnology, Inc. (NASDAQ:UBX), we note that the average 3-month trading volume was 1.5 Million, while that of the preceding 10-day period stands at 889.78 Million. Current shares outstanding are 52.04 Million.

According to data from Thomson Reuters, insiders hold 19.4% of the company’s shares while institutions hold 70.98%. The data shows that short shares as of August 30, 2020, stood at 3.57 Million at a short ratio of 1.1. This represents a 6.86% Short interest in Shares outstanding on August 30, 2020. Shares short dropped in August from the previous month at 5.38 Million. Investors should be excited about this stock as its upside potential is great, with today’s price pushing the stock -51.04% down in year-to-date price movement.